Elizabeth Leung

Elizabeth Leung

Auto-generated profile, based on publicly available information

Elizabeth Leung

St. Michael’s Hospital, Department of Pharmacy, Unity Health Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2021 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ELElizabeth Leung
Elizabeth Leung
RCRyan L. Crass
Ryan L. Crass
SJSarah C. J. Jorgensen
Sarah C. J. Jorgensen
SRSumit Raybardhan
Sumit Raybardhan
BLBradley J. Langford
Bradley J. Langford
NRNathaniel Rhodes
Nathaniel Rhodes

28 July 2022 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
MEMarion Elligsen
Marion Elligsen
MWMichael Wan
Michael Wan
PLPhilip W. Lam
Philip W. Lam
JLJennifer Lo
Jennifer Lo
LTLinda R. Taggart
Linda R. Taggart
ELElizabeth Leung
Elizabeth Leung
Objective: To describe the evolution of respiratory antibiotic prescribing during the coronavirus disease 2019 (COVID-19) pandemic across 3 large hospitals that maintained antimicrobial stewardship services throughout the pandemic. Design: Retrospective interrupted time-series analysis. Setting: A multicenter study was conducted including medical and intensive care units (ICUs) from 3 hospitals within a Canadian epicenter for COVID-19. Methods: Interrupted time-series analysis was used to analyze rates of respiratory antibiotic utilization measured in days of therapy per 1,000 patient days (DOT/1,000 PD) in medical units and ICUs. Each of the first 3 waves of the pandemic were compared to the baseline. Results: Within the medical units, use of respiratory antibiotics increased during the first wave of the pandemic (rate ratio [RR], 1.76; 95% CI, 1.38–2.25) but returned to the baseline in waves 2 and 3 despite more COVID-19 admissions. In ICU, the use of respiratory antibiotics increased in wave 1 (RR, 1.30; 95% CI, 1.16–1.46) and wave 2 of the pandemic (RR, 1.21; 95% CI, 1.11–1.33) and returned to the baseline in the third wave, which had the most COVID-19 admissions. Conclusions: After an initial surge in respiratory antibiotic prescribing, we observed the normalization of prescribing trends at 3 large hospitals throughout the COVID-19 pandemic. This trend may have been due to the timely generation of new research and guidelines developed with frontline clinicians, allowing for the active application of new research to clinical practice.

7 November 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
LELauren Epstein
Lauren Epstein
DDDaniel J. Diekema
Daniel J. Diekema
DMDaniel J. Morgan
Daniel J. Morgan
MFMohamad G. Fakih
Mohamad G. Fakih
FLFrancesca Lee
Francesca Lee
MHMary K. Hayden
Mary K. Hayden
Executive summary: The coronavirus disease 2019 (COVID-19) pandemic has demonstrated the importance of stewardship of viral diagnostic tests to aid infection prevention efforts in healthcare facilities. We highlight diagnostic stewardship lessons learned during the COVID-19 pandemic and discuss how diagnostic stewardship principles can inform management and mitigation of future emerging pathogens in acute-care settings. Diagnostic stewardship during the COVID-19 pandemic evolved as information regarding transmission (eg, routes, timing, and efficiency of transmission) became available. Diagnostic testing approaches varied depending on the availability of tests and when supplies and resources became available. Diagnostic stewardship lessons learned from the COVID-19 pandemic include the importance of prioritizing robust infection prevention mitigation controls above universal admission testing and considering preprocedure testing, contact tracing, and surveillance in the healthcare facility in certain scenarios. In the future, optimal diagnostic stewardship approaches should be tailored to specific pathogen virulence, transmissibility, and transmission routes, as well as disease severity, availability of effective treatments and vaccines, and timing of infectiousness relative to symptoms. This document is part of a series of papers developed by the Society of Healthcare Epidemiology of America on diagnostic stewardship in infection prevention and antibiotic stewardship.1

6 February 2023 in Infectious Medicine
Verified
Journal Article
Open access
ACApril J. Chan
April J. Chan
GLGerald Lebovic
Gerald Lebovic
MWMichael Wan
Michael Wan
YCYan Chen
Yan Chen
ELElizabeth Leung
Elizabeth Leung
MDMark Downing
Mark Downing
Studies have demonstrated improved clinical outcomes with extended infusion (EI) piperacillin/tazobactam (TZP) compared to standard infusion (SI). However, there is less evidence on its benefits in noncritically-ill patients. Hospital-wide EI TZP was implemented at our site on February 21, 2012. Our objectives were to compare clinical, safety and economic outcomes between EI and SI TZP. A retrospective cohort study of all adult patients who received EI TZP (3.375 g IV q8h infused over 4 hours and SI TZP for ≥ 48 hours during 3 years pre-and postimplementation was conducted. The primary study outcome was 14-day mortality while secondary outcomes included length of hospital stay (LOS), nursing plus pharmacy cost, occurrence of Clostridioides difficile infection, readmission within 30 days and change in Pseudomonas aeruginosa minimum inhibitory concentration (MIC) distribution for TZP. The primary outcome and binary secondary outcomes were analyzed using a logistic regression model. LOS was examined using time to event analysis. Cost was examined using linear regression modelling. Overall, 2034 patients received EI TZP and 1364 patients received SI TZP. EI TZP was associated with lower odds of mortality (OR 0.76, 95% CI 0.63–0.91), lower odds of C. difficile infection (OR 0.59, 95% CI 0.41–0.84) and 8% lower cost (estimate 0.92, 95% CI 0.87–0.98) compared to SI TZP. Hospital-wide implementation of EI TZP was associated with lower odds of 14-day mortality and incidence of C. difficile infection with cost savings at our institution.

30 June 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
EAEllen Germaine Avery
Ellen Germaine Avery
TLTaylor Laughlin
Taylor Laughlin
KBKevin Brown
Kevin Brown
LMLarissa M. Matukas
Larissa M. Matukas
ELElizabeth Leung
Elizabeth Leung
We evaluated the impact of recent revisions to the Clinical and Laboratory Standards Institute (CLSI) aminoglycoside breakpoints on susceptibility within Enterobacterales and Pseudomonas aeruginosa at a Canadian academic hospital. While the aminoglycoside breakpoint changes minimally affected overall susceptibility, the impact of these changes was notable within beta-lactamase producing Enterobacterales.

2 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ELElizabeth Leung
Elizabeth Leung
SJSarah C.J. Jorgensen
Sarah C.J. Jorgensen
RCRyan L. Crass
Ryan L. Crass
SRSumit Raybardhan
Sumit Raybardhan
BLBradley Langford
Bradley Langford
NRNathaniel Rhodes
Nathaniel Rhodes
Tocilizumab is one of few treatments that have been shown to improve mortality in patients with COVID-19, but increased demand has led to relative global shortages. Recently, it has been suggested that lower doses, or fixed doses, of tocilizumab could be a potential solution to conserve the limited global supply while conferring equivalent therapeutic benefit to the dosing regimens studied in major trials. The relationship between tocilizumab dose, exposure, and response in COVID-19 has not been adequately characterized. There are a number of pharmacokinetic (PK) parameters which likely differ between patients with severe COVID-19 and patients in whom tocilizumab was studied during the FDA approval process. Likewise, it is unclear whether a threshold exposure is necessary for tocilizumab efficacy. The safety and efficacy of fixed versus weight-based dosing of tocilizumab has been evaluated outside of COVID-19, but it is uncertain if these observations are generalizable to severe or critical COVID-19. In the current review, we consider the potential advantages and limitations of alternative tocilizumab dosing strategies. Leveraging PK models and simulation analyses, we demonstrate that a fixed single dose of tocilizumab 400 mg is unlikely to produce PK exposures equivalent to those achieved in the REMAP-CAP trial, though weight-stratified dosing appears to produce more uniform exposure distribution. Data from current and future trials could provide PK/PD insight to better inform dosing strategies at the bedside. Ultimately, rational dosing strategies that balance available limited supply with patient needs are required.